P205 SWITCH FROM OMALIZUMAB TO MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: EFFECT OF WEIGHT AND BMI
Annals of Allergy, Asthma & Immunology(2020)
Abstract
In the OSMO study, patients with severe eosinophilic asthma (SEA) not optimally controlled with high-dose inhaled corticosteroids and other controller(s) plus omalizumab were switched to mepolizumab. In this post hoc analysis of OSMO data we evaluated mepolizumab treatment response, by weight and body mass index (BMI).
MoreTranslated text
Key words
asthma,omalizumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined